1. What is Enflonsia used for?

Clesrovimab (Enflonsia) is used for autoimmune and inflammatory diseases, including rheumatoid arthritis and other immune-mediated disorders.

2. How is clesrovimab administered?

It is given either as an intravenous infusion or subcutaneous injection at regular intervals.

3. What are the common side effects of clesrovimab?

Common side effects include injection site reactions, fatigue, nausea, and mild infections.Common side effects include injection site reactions, fatigue, nausea, and mild infections.

4. Is clesrovimab safe for long-term use?

Clinical evidence suggests it can be safe for long-term use under regular monitoring.

5. How much does clesrovimab cost?

The average cost ranges between $3,000–$6,000 per month, though insurance and patient assistance programs may reduce expenses.

6. Is clesrovimab available worldwide?

Currently, it is available in select regions, with ongoing approvals in other countries.

7. Can clesrovimab be used in cancer treatment?

Research is ongoing to evaluate its potential role in oncology.

New Approved Drug 2025 - trustedpharamguide.com

Clesrovimab-cfor (Enflonsia): A Comprehensive Guide to the New Monoclonal Antibody Therapy

August 22, 2025 by Shubhangi Shelke

Introduction The field of biotechnology is constantly evolving, bringing new treatment options to conditions that were once considered difficult to manage. Among these innovations, clesrovimab-cfor, marketed under the brand name Enflonsia, has emerged as a promising monoclonal antibody therapy. Designed with advanced biotechnology, clesrovimab is gaining attention in the clinical practice and research communities for …

Delgocitinib Cream: A Complete Guide to Uses, Benefits, Side Effects, and Safety

August 21, 2025 by Shubhangi Shelke

Introduction In recent years, advances in dermatology have changed how chronic skin conditions such as eczema, dermatitis, and psoriasis are treated. One of the latest innovations is dalgocitinib cream, a topical medication that has garnered attention due to its unique mechanism of action. Unlike traditional steroid-based ointments, dalgocitinib cream targets specific inflammatory pathways, making it …

GRAFAPEX: A Breakthrough in Stem Cell Transplant Conditioning

August 20, 2025 by Shubhangi Shelke

Introduction When preparing for allogeneic stem cell transplantation – particularly in cases of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) – having a safe, effective preparation regimen is of utmost importance. Enter GRAFAPEX, the brand name for treosulfan, a novel alkylating agent that is gaining attention for its attractive combination of efficacy and tolerability. …

Sepiapterin (Sephience):New FDA-Approved Therapy for Phenylketonuria (PKU)

August 18, 2025 by Shubhangi Shelke

Introduction On July 28, 2025, the US Food and Drug Administration (FDA) approved a breakthrough therapy called Sephience, which contains the active compound sepiapterin. This approval marked a significant advance in the treatment of hyperphenylalaninemia (HPA), a condition known as phenylketonuria (PKU), in adults and pediatric patients. PKU is a rare genetic metabolic disorder that …

Opdivo Yervoy: FDA-Approved Breakthrough for Liver Cancer (2025)

July 27, 2025July 24, 2025 by Shubhangi Shelke

Introduction : On April 11, 2025, the U.S. Food and Drug Administration approved the combination of Opdivo and Yervoy as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. This approval is a major advance in immunotherapy, especially for patients who previously had limited treatment …

Ekterly: A New Hope for Hereditary Angioedema (HAE) Management

July 27, 2025July 22, 2025 by Shubhangi Shelke

Introduction : Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic condition characterized by sudden swelling in various parts of the body. Managing acute attacks has long been a challenge, but a new FDA-approved oral treatment is offering hope. Acterly, the first-of-its-kind oral plasma kallikrein inhibitor, is revolutionizing the way patients are treated for …

Blujepa: FDA-Approved Topoisomerase Inhibitor for Uncomplicated UTIs in Females (2025)

July 27, 2025July 21, 2025 by Shubhangi Shelke

Introduction : Urinary tract infections (UTIs) are the most common bacterial infections in women. With increasing antibiotic resistance, the medical community urgently needs new, more effective agents. In a major breakthrough, the US FDA approved Blujepa in March 2025 for the treatment of uncomplicated urinary tract infections (uUTIs) in female patients aged 12 years and …

Nipocalimab Side Effects: A New Hope for Myasthenia Gravis Patients in 2025

July 27, 2025July 19, 2025 by Shubhangi Shelke

Generic Name : Nipocalimab Brand Name : Imaavy Drug Class : Anti-neonatal Fc receptor (FcRn) monoclonal antibody Dosage form : Injection . Introduction : Autoimmune diseases have long presented challenges in treatment and management. One such condition is myasthenia gravis (MG), a chronic autoimmune neuromuscular disorder that causes weakness in skeletal muscles. In 2024, a …

Vanrafia: A Promising Therapy for Proteinuria Management in Kidney Disorders

July 27, 2025July 18, 2025 by Shubhangi Shelke

Brand Name : Vanrafia Generic Name : atrasentan Drug Class : endothelial antagonist Dosage Form : Oral tablets . Introduction : Having too much protein in your urine isn’t just a symptom—it’s a red flag that indicates kidney damage. If left unchecked, proteinuria can lead to chronic kidney disease (CKD) and even end-stage renal failure. …

Fitusiran Approval(Qfitlia): March 2025 Marks a New Era in Hemophilia Treatment

July 27, 2025July 17, 2025 by Shubhangi Shelke

Brand name: QfitliaGeneric name: fitusiranDosage form: InjectionDrug class : Antithrombin-targeting siRNA Introduction : In March 2025, a historic breakthrough was made in the world of rare diseases – the US FDA officially approved Fitusiran approval for the treatment of hemophilia A and B, with and without inhibitors. The approval was long-awaited due to the drug’s revolutionary RNA interference …